Moreover, clinical utility of selpercatinib was showed also in a neoadjuvant setting, determining a RECIST response greater than 50% followed by complete surgical resection in a RET-mutated MTC patient with initially unresectable, widely metastatic disease (142). The gene discussed is RET; the disease is medullary thyroid gland carcinoma.